|Mr. Mark J. Enyedy||Chief Exec. Officer, Pres and Director||568.98k||N/A||53|
|Mr. David B. Johnston||Chief Financial Officer and Exec. VP||279.44k||N/A||62|
|Dr. Richard J. Gregory Ph.D.||Chief Scientific Officer and Exec. VP||312.48k||N/A||59|
|Dr. Anna Berkenblit M.D., MM.Sc||Chief Medical Officer and VP||269.23k||N/A||47|
|Ms. Carol Hausner||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 2.